HHS Panel Discusses Pros/Cons of Big Data in Clinical Research

Clinical Trials Advisor
Must investigators obtain informed consent anew in order to use aggregated clinical trial data for secondary purposes? What purpose does this data serve to improve standards of care? And are there risks inherent in using such data?

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00